Abstract

The goal of this project it to better understand the natural history of Lyme disease and possible causes for persisting symptoms. We plan to develop reliable objective markers of infection, of clinical status and of host responses to the organism in order to discern the scope and the implications of persistent borrelial infection, the effectiveness of current treatment options, and the development of new therapeutics approaches. For that, a clinical protocol was developed and approved by the NIAID IRB. The study is assembling a well characterized cohort of patients with presumed chronic Lyme disease and relevant controls. These patients are being extensively evaluated in a cross-sectional study and the neuroborreliosis patients will be followed prospectively after therapy with intervenous ceftriaxone. These studies will yield a prospective database upon which stringent diagnostic criteria can be established and future therapeutic trials can be designed. At this point, 18 patients have been enrolled in the study. This study is in its early phase of development, and, at this point, it is too early to draw conclusions from the analysis of the results of the multiple and extensive testing done in the enrolled patients

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000695-02
Application #
6160703
Study Section
Special Emphasis Panel (LCI)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Sherman, Kenneth E; Andersen, Janet W; Butt, Adeel A et al. (2010) Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr 55:597-605
Schwan, Tom G; Raffel, Sandra J; Schrumpf, Merry E et al. (2009) Tick-borne relapsing fever and Borrelia hermsii, Los Angeles County, California, USA. Emerg Infect Dis 15:1026-31
Marques, Adriana; Brown, Margaret R; Fleisher, Thomas A (2009) Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls. Clin Vaccine Immunol 16:1249-50
Lunemann, Jan D; Gelderblom, Harald; Sospedra, Mireia et al. (2007) Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis. Infect Immun 75:243-51
Cassiani-Ingoni, Riccardo; Cabral, Erik S; Lunemann, Jan D et al. (2006) Borrelia burgdorferi Induces TLR1 and TLR2 in human microglia and peripheral blood monocytes but differentially regulates HLA-class II expression. J Neuropathol Exp Neurol 65:540-8
Cabral, Erik S; Gelderblom, Harald; Hornung, Ronald L et al. (2006) Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. J Infect Dis 193:849-59
Marques, Adriana R; Hornung, Ronald L; Dally, Len et al. (2005) Detection of immune complexes is not independent of detection of antibodies in Lyme disease patients and does not confirm active infection with Borrelia burgdorferi. Clin Diagn Lab Immunol 12:1036-40
Philipp, Mario T; Wormser, Gary P; Marques, Adriana R et al. (2005) A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis. Clin Diagn Lab Immunol 12:1069-74
Fleming, R V; Marques, A R; Klempner, M S et al. (2004) Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis. Eur J Clin Microbiol Infect Dis 23:615-8
Gelderblom, Harald; Martin, Roland; Marques, Adriana R (2004) Research opportunities on human neuroborreliosis. Vector Borne Zoonotic Dis 4:261-72

Showing the most recent 10 out of 22 publications